In an additional study, targeting PLGA nanoparticles loaded with the TAA Trp2 and gp100 to CLEC9A expressing DCs via antibodies resulted in strong therapeutic anti-tumor responses in vivo, but also induced in vitro expansion of NKT and CD8+ T cells specific for melanoma in PBMCs from both healthy donors and melanoma patients (114). Here, CLEC9A is linked to melanoma.